AMAG Pharma (AMAG) Posts Smaller Q4 Loss

February 7, 2019 7:08 AM EST

AMAG Pharma (NASDAQ: AMAG) reported Q4 EPS of ($0.64), $0.45 better than the analyst estimate of ($1.09). Revenue for the quarter came in at $88.1 million versus the consensus estimate of $98.92 million.

GUIDANCE:

AMAG Pharma sees FY2019 revenue of $365-415 million, versus the consensus of $382.51 million.

For earnings history and earnings-related data on AMAG Pharma (AMAG) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings